David Alvin Cooper
Chief Executive Officer Biagon
David Cooper is Co-Founder & CEO of Biagon, a computational drug discovery company focused on GPCR biased signaling. He co-developed a patent-pending machine-learning algorithm that predicts how ligands modulate signaling pathways in living cells — accelerating the design of safer and more effective GPCR-targeted therapies. Before Biagon, David conducted research on GPCR conformational dynamics, including studies relating intracellular pocket conformations and efficacy at the μ-opioid receptor. His work bridges computational biology, pharmacology, and translational innovation.
Seminars
Tuesday 28th April 2026
Revealing the Dynamic Pathways of GPCR Bias Through Integrated Modeling & Pharmacology to Accelerate Discovery of Functionally Selective Therapeutics
9:30 am
- Utilising AI and physics-based simulations to reveal conformational signatures behind G-protein vs β-arrestin signaling
- Integrate simulations with pharmacology to turn conformational insight into measurable biological outcomes
- Sharing case studies translating structural insights and pharmacology predictions into the discovery of biased GPCR candidates
